Statistical flag only — not an accusation of fraud
⚠️ This provider averages 1.3K services per working day — physically unusual for an individual practitioner
Based on 3.3M total services over 10 years (250 working days/year). Learn about impossible service volumes →
This provider's $45.2M in total Medicare payments ranks in the 99th percentile of Hematology-Oncology providers nationally.
Averaging 1.3K services per working day raises questions about billing patterns.
Medicare payments to this provider grew 158% from 2014 to 2023.
This provider has been statistically flagged with a risk score of 70/100. Statistical flags are not accusations of fraud.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $45.45 | $13.90 | 3.27x | $31.55 | $2.0M | 141.6K | 45 |
| 2015 | $39.97 | $13.02 | 3.07x | $26.95 | $2.8M | 215.4K | 48 |
| 2016 | $43.35 | $13.67 | 3.17x | $29.68 | $3.8M | 277.4K | 44 |
| 2017 | $40.38 | $12.20 | 3.31x | $28.18 | $4.0M | 324.4K | 53 |
| 2018 | $47.91 | $12.82 | 3.74x | $35.09 | $5.5M | 427.6K | 53 |
| 2019 | $44.98 | $12.32 | 3.65x | $32.66 | $4.8M | 392.4K | 53 |
| 2020 | $57.86 | $14.06 | 4.12x | $43.80 | $5.9M | 417.9K | 48 |
| 2021 | $53.51 | $14.04 | 3.81x | $39.47 | $6.1M | 436.2K | 54 |
| 2022 | $64.84 | $14.33 | 4.52x | $50.51 | $5.3M | 370.7K | 50 |
| 2023 | $68.06 | $15.20 | 4.48x | $52.86 | $5.1M | 334.4K | 53 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 160.4K | $6.5M | $40.81 | 2.94x |
| J9299 | Injection, nivolumab, 1 mg | 230.8K | $5.0M | $21.70 | 2.88x |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.7K | $5.0M | $2.9K | 2.87x |
| J0897 | Injection, denosumab, 1 mg | 232.4K | $3.5M | $15.17 | 2.84x |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 34.1K | $2.5M | $74.51 | 2.84x |
| J9035 | Injection, bevacizumab, 10 mg | 36.3K | $2.0M | $54.67 | 2.65x |
| J9310 | Injection, rituximab, 100 mg | 3.1K | $1.8M | $584.39 | 2.39x |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 30.3K | $1.6M | $51.50 | 2.62x |
| J9306 | Injection, pertuzumab, 1 mg | 121.0K | $1.2M | $10.14 | 3.45x |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 14.7K | $1.2M | $79.80 | 3.04x |
| J9022 | Injection, atezolizumab, 10 mg | 18.2K | $1.0M | $56.05 | 8.31x |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 21.6K | $1.0M | $47.14 | 6.79x |
| J9041 | Injection, bortezomib, 0.1 mg | 33.4K | $981.8K | $29.35 | 3.86x |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 10.3K | $946.4K | $91.54 | 4.52x |
| J9395 | Injection, fulvestrant, 25 mg | 19.6K | $932.6K | $47.46 | 4.94x |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | 93.0K | $905.2K | $9.73 | 2.75x |
| J9311 | Injection, rituximab 10 mg and hyaluronidase | 25.6K | $766.7K | $29.97 | 4.00x |
| J9312 | Injection, rituximab, 10 mg | 9.1K | $652.9K | $71.74 | 2.96x |
| J2469 | Injection, palonosetron hcl, 25 mcg | 61.7K | $602.6K | $9.76 | 6.10x |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 56.0K | $515.5K | $9.21 | 3.61x |
This provider submits charges 3.82 times higher than what Medicare actually pays.
A markup ratio of 3.82x means for every $100 Medicare pays, this provider initially charges $382. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Hematology-Oncology providers in MS for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Guangzhi Qu, M.D. | Jackson, MS | $55.7M | ⚠️ Flagged |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data